FDA approves cervical cancer DNA test

Share this article:

Test specifically identifies HPV types 16 and 18, as well as detecting 12 other types of high-risk HPVs.

The new diabetes test helps identify patients with type 1 diabetes
The new diabetes test helps identify patients with type 1 diabetes

HealthDay News -- The FDA has approved the first human papillomavirus (HPV) DNA test for women aged 25 years and older that can be used to assess the need for a woman to undergo additional diagnostic testing for cervical cancer.

The cobas HPV Test uses cervical cell samples to specifically identify HPV  types 16 and 18, the two types responsible for approximately 70% of cervical cancers, and also detects 12 other types of high-risk HPVs at the same time.

In addition, the test can provide information about a patient's future risk for developing cervical cancer.

Women who test positive for HPV 16 or 18 should have a colposcopy, and women testing positive for at least one of the 12 other high-risk HPV types should have a Pap test to determine the need for a colposcopy.

Other information should be used by health care professionals in conjunction with the cobas HPV Test results, including the patient's screening history and risk factors, as well as current professional guidelines.

The cobas HPV Test's safety and effectiveness were evaluated in a study of more than 40,000 women 25 years and older who underwent routine cervical exams. Women who had a positive Pap test or whose cervical cells screened positive for HPV, as well as a subset of women whose Pap and HPV tests were both negative, underwent a colposcopy and cervical tissue biopsy

The biopsy results were compared to the Pap and cobas HPV Test results. Results from this study, including three-year follow-up data indicated that the cobas HPV Test was safe and effective for use as a primary screening tool for cervical cancer.

The cobas HPV Test is manufactured by Roche Molecular Systems Inc., based in Pleasanton, Calif.

More Information

Share this article:
You must be a registered member of Clinical Advisor to post a comment.

More in Web Exclusives

DHEA serum levels predict coronary heart disease risk

DHEA serum levels predict coronary heart disease risk

For elderly men, low serum levels of the adrenal sex hormone DHEA and its sulfate, DHEA-S, predict coronary heart disease risk.

Prenatal exposure to sodium valproate linked to lower IQ in offspring

Prenatal exposure to sodium valproate linked to lower ...

The IQ of children exposed to VPA was lower compared with children born to women without epilepsy and that of those exposed to carbamazepine.

FDA approves first Meningococcal B vaccine

FDA approves first Meningococcal B vaccine

The FDA has approved Trumenba, the first vaccine approved in the U.S. to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B